Literature DB >> 21135383

Neurocognitive sequelae in African American and Caucasian children with multiple sclerosis.

K A Ross1, D C Schwebel, J Rinker, J Ness, J Ackerson.   

Abstract

OBJECTIVE: To examine domain-specific neurocognitive differences between African American (AA) and Caucasian (CA) patients with pediatric-onset multiple sclerosis (POMS).
METHODS: An extensive battery of neuropsychological tests was given to each subject, including tests in all major domains of cognitive function. Point-biserial correlations between ethnicity and test performance were computed. Significant correlations were followed up with hierarchical multiple regression analysis, accounting for clinical and demographic variables before examining ethnic differences.
RESULTS: Forty-two patients with POMS including 20 AA and 22 CA subjects were assessed. The cohorts did not differ in age, gender, socioeconomic status, disease duration, disability score, immunoglobulin G index, or number of relapses in the first 2 years of disease. Retaining some of these variables as covariates in the hierarchical regression analysis, the AA cohort performed worse on measures of language (p < 0.001) and complex attention (p < 0.01) than their CA peers.
CONCLUSION: AA patients with POMS may be at higher risk for adverse cognitive impact in the areas of language and complex attention. Longitudinal characterization of cognitive pathology is critical for the development of effective intervention strategies to prolong cognitive functioning in POMS cohorts.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21135383      PMCID: PMC3385422          DOI: 10.1212/WNL.0b013e318200d7b9

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  17 in total

1.  Ethnicity and mortality from systemic lupus erythematosus in the US.

Authors:  E Krishnan; H B Hubert
Journal:  Ann Rheum Dis       Date:  2006-04-20       Impact factor: 19.103

2.  Higher IgG index found in African Americans versus Caucasians with multiple sclerosis.

Authors:  John R Rinker; Kathryn Trinkaus; Robert T Naismith; Anne H Cross
Journal:  Neurology       Date:  2007-07-03       Impact factor: 9.910

3.  Pediatric-onset multiple sclerosis in African-American black and European-origin white patients.

Authors:  Aaron L Boster; Christina F Endress; Stephanie A Hreha; Christina Caon; Jai S Perumal; Omar A Khan
Journal:  Pediatr Neurol       Date:  2009-01       Impact factor: 3.372

4.  Rates of autoimmune diseases in Kaiser Permanente for use in vaccine adverse event safety studies.

Authors:  Nicola P Klein; Paula Ray; Diane Carpenter; John Hansen; Edwin Lewis; Bruce Fireman; Steven Black; Claudia Galindo; Johannes Schmidt; Roger Baxter
Journal:  Vaccine       Date:  2009-11-05       Impact factor: 3.641

5.  Ethnic disparities among patients with systemic lupus erythematosus in South Carolina.

Authors:  Erica Anderson; Paul J Nietert; Diane L Kamen; Gary S Gilkeson
Journal:  J Rheumatol       Date:  2008-03-15       Impact factor: 4.666

6.  Cognitive and psychosocial features of childhood and juvenile MS.

Authors:  M P Amato; B Goretti; A Ghezzi; S Lori; V Zipoli; E Portaccio; L Moiola; M Falautano; M F De Caro; M Lopez; F Patti; R Vecchio; C Pozzilli; V Bianchi; M Roscio; G Comi; M Trojano
Journal:  Neurology       Date:  2008-05-13       Impact factor: 9.910

7.  Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis.

Authors:  Mark P Gorman; Brian C Healy; Mariann Polgar-Turcsanyi; Tanuja Chitnis
Journal:  Arch Neurol       Date:  2009-01

8.  Modification of Multiple Sclerosis Phenotypes by African Ancestry at HLA.

Authors:  Bruce A C Cree; David E Reich; Omar Khan; Philip L De Jager; Ichiro Nakashima; Toshiyuki Takahashi; Amit Bar-Or; Christine Tong; Stephen L Hauser; Jorge R Oksenberg
Journal:  Arch Neurol       Date:  2009-02

9.  Natural history of multiple sclerosis with childhood onset.

Authors:  Christel Renoux; Sandra Vukusic; Yann Mikaeloff; Gilles Edan; Michel Clanet; Bénédicte Dubois; Marc Debouverie; Bruno Brochet; Christine Lebrun-Frenay; Jean Pelletier; Thibault Moreau; Catherine Lubetzki; Patrick Vermersch; Etienne Roullet; Laurent Magy; Marc Tardieu; Samy Suissa; Christian Confavreux
Journal:  N Engl J Med       Date:  2007-06-21       Impact factor: 91.245

10.  Medical insurance, socioeconomic status, and age of onset of endstage renal disease in patients with lupus nephritis.

Authors:  Michael M Ward
Journal:  J Rheumatol       Date:  2007-08-01       Impact factor: 4.666

View more
  5 in total

1.  Cognitive impairment occurs in children and adolescents with multiple sclerosis: results from a United States network.

Authors:  Laura Julian; Dana Serafin; Leigh Charvet; Joseph Ackerson; Ralph Benedict; Ellen Braaten; Tanya Brown; Ellen O'Donnell; Joy Parrish; Thomas Preston; Michael Zaccariello; Anita Belman; Tanuja Chitnis; Mark Gorman; Jayne Ness; Marc Patterson; Moses Rodriguez; Emmanuelle Waubant; Bianca Weinstock-Guttman; Ann Yeh; Lauren B Krupp
Journal:  J Child Neurol       Date:  2012-11-15       Impact factor: 1.987

2.  Cognitive Functioning in Patients with Pediatric-Onset Multiple Sclerosis, an Updated Review and Future Focus.

Authors:  Joy B Parrish; Emily Fields
Journal:  Children (Basel)       Date:  2019-02-04

3.  Cognitive impairment in multiple sclerosis: a forgotten disability remembered.

Authors:  Kristen Rahn; Barbara Slusher; Adam Kaplin
Journal:  Cerebrum       Date:  2012-11-30

4.  Race, ethnicity, and cognition in persons newly diagnosed with multiple sclerosis.

Authors:  Lilyana Amezcua; Jessica B Smith; Edlin G Gonzales; Samantha Haraszti; Annette Langer-Gould
Journal:  Neurology       Date:  2020-03-09       Impact factor: 11.800

5.  Progression, symptoms and psychosocial concerns among those severely affected by multiple sclerosis: a mixed-methods cross-sectional study of Black Caribbean and White British people.

Authors:  Jonathan Koffman; Wei Gao; Cassie Goddard; Rachel Burman; Diana Jackson; Pauline Shaw; Fiona Barnes; Eli Silber; Irene J Higginson
Journal:  PLoS One       Date:  2013-10-02       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.